| 2016-12 |
Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation |
Oncotarget. 2016 Dec;7(52):86239-86256. |
 |
| 2016-12 |
Novel cKIT kinase inhibitor, BPRCKJ001, as an advanced therapeutic candidate for GIST |
Annals of Oncology. 2016 Dec;27(Suppl. 9):Meeting Abstract 2P. |
|
| 2016-10 |
BPR1J373, an oral multiple tyrosine kinase inhibitor, targets c-KIT for the treatment of c-KIT driven myeloid leukemia |
Molecular Cancer Therapeutics. 2016 Oct;15(10):2323-2333. |
|
| 2016-10 |
Multifunctional nanoparticles for oral protein drug delivery |
Diabetes Research and Clinical Practice. 2016 Oct;120(Suppl. 1):S19. |
|
| 2016-08 |
Dipeptidyl peptidase-4 inhibitor LAF-237 improves glucose tolerance and expends graft beta cell mass in diabetic mice transplanted with a sufficient number of islets |
Diabetologia. 2016 Aug;59(Suppl. 1):S198. |
|
| 2016-05 |
N-Indolylglycosides bearing modifications at the glucose C6-Position as Sodium-Dependent Glucose Co-transporter 2 inhibitors |
Bioorganic and Medicinal Chemistry. 2016 May;24(10):2242-2250. |
|
| 2016-02 |
Multifunctional nanoparticles for oral protein drug delivery |
Nanomedicine: Nanotechnology, Biology and Medicine. 2016 Feb;12(2):463. |
|
| 2015-09 |
Self-assembling bubble carriers for oral protein delivery |
Biomaterials. 2015 Sep;64:115-124. |
|
| 2015-08 |
Novel Nrf2/ARE activator, trans-coniferylaldehyde, induces a HO-1-mediated defense mechanism through a dual p38alpha/MAPKAPK-2 and PK-N3 signaling pathway |
Chemical Research in Toxicology. 2015 Aug ;28(9):1681-1692. |
|
| 2015-08 |
Zinc-dipicolylamine directed pharmaceutical delivery system (ZAPS) as an innovative cancer drug delivery platform |
Cancer Research. 2015 Aug;75(Suppl. 15):Abstract number 4413. |
|
| 2015-08 |
Optimization of quinazoline-based kinase inhibitors: Identification of a dual FLT3/AURKA kinase inhibitor for the treatment of acute myeloid leukemia |
Abstracts of Papers of the American Chemical Society. 2015 Aug;250:Meeting Abstract 490. |
|
| 2015-07 |
Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations |
European Journal of Medicinal Chemistry. 2015 Jul;100:151-161. |
|
| 2015-04 |
IL-1beta promotes malignant transformation and tumor aggressiveness in oral cancer |
Journal of Cellular Physiology. 2015 APR;230(4):875-884. |
|
| 2015-03 |
Stem cell mobilizers targeting chemokine receptor CXCR4: Renoprotective application in acute kidney injury |
Journal of Medicinal Chemistry. 2015 Mar;58(5):2315-2325. |
|
| 2014-11 |
Discovery of multiple kinases inhibitors, DBPR114, as the novel anti-cancer agent |
European Journal of Cancer. 2014 Nov;50(Suppl. 6):92-93. |
|
| 2014-10 |
YYEI motif is critical to oncogenicity of 14-3-3 proteins |
Cancer Research. 2014 Oct;74(19 Suppl.):Abstract No. 3527. |
|
| 2014-10 |
Novel irreversible EGFR tyrosine kinase inhibitor, DBPR112, as a therapeutic candidate for lung adenocarcinoma |
Cancer Research. 2014 Oct;74(19 Suppl.):Abstract No. 1756. |
|
| 2014-08-15 |
Anticancer oral formulation |
特許第5596680號/2014-08-15 |
|
| 2014-08-04 |
Effects of dipeptidyl peptidase-4 inhibition with MK-0431 on syngeneic mouse islet transplantation |
International Journal of Endocrinology. 2014 Aug 4;2014:Article ID 795283. |
|
| 2014-06-04 |
抗癌口服制剂 |
ZL200980126979.4/2014-06-04 |
|
| 2014-04 |
Treatment of chemotherapy-induced neutropenia in a rat model by using multiple daily doses of oral administration of G-CSF-containing nanoparticles |
Biomaterials. 2014 Apr;35(11):3641-3649. |
|
| 2014-03 |
DBPR112, a potent and selective EGFR kinase inhibitor in preclinical study |
Abstracts of Papers - American Chemical Society. 2014 Mar;247:Article number 315-MEDI. |
|
| 2014-01-08 |
Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer |
PLoS ONE. 2014 Jan 8;9(1):Article number e83160. |
|
| 2013-11 |
BPR0C305, an orally active microtubule-disrupting anticancer agent |
Anticancer Drugs. 2013 Nov;24(10):1047-1057. |
|
| 2013-11 |
A development drug candidate targeting EGFR kinase for lung cancer: DBPR112 |
Journal of Thoracic Oncology. 2013 Nov;8(Suppl. 2):S779-S780. |
|
